naphthalimides has been researched along with Stomach Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, J; Li, E; Li, L; Wu, Y; Zhang, G | 1 |
| Aravind, A; Ashktorab, H; Chatterjee, A; Dagamajalu, S; Gowda, H; Modi, PK; Najar, MA; Prasad, TSK; Sidransky, D; Smoot, DT | 1 |
| Appella, DH; Chen, Z; Huang, S; Liu, Y; Lou, G; Norton, JT; Wang, C; Witschi, MA; Xu, Q | 1 |
| Bauman, A; Benson, AB; Blough, RR; Carroll, RB; French, SL; Kilton, LJ; Mullane, MR; Schilsky, RL; Wade, JL | 1 |
1 trial(s) available for naphthalimides and Stomach Neoplasms
| Article | Year |
|---|---|
Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial.
Topics: Adenine; Adenocarcinoma; Antineoplastic Agents; Female; Hematologic Diseases; Humans; Imides; Isoquinolines; Male; Naphthalimides; Organophosphonates; Stomach Neoplasms | 1994 |
3 other study(ies) available for naphthalimides and Stomach Neoplasms
| Article | Year |
|---|---|
Targeting DNA and mutant p53 by a naphthalimide derivative, NA20, exhibits selective inhibition in gastric tumorigenesis by blocking mutant p53-EGFR signaling pathway.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; DNA; ErbB Receptors; Genes, p53; Humans; Male; Mice; Mice, Inbred BALB C; Naphthalimides; Oncogene Protein p21(ras); Signal Transduction; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Hyperactivation of MEK/ERK pathway by Ca
Topics: Benzimidazoles; Calcium-Calmodulin-Dependent Protein Kinase Kinase; CDC2 Protein Kinase; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromatography, Liquid; Cyclin-Dependent Kinase 2; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Naphthalimides; Phosphorylation; Proteomics; Stomach Neoplasms; Tandem Mass Spectrometry | 2021 |
Methoxyethylamino-numonafide is an efficacious and minimally toxic amonafide derivative in murine models of human cancer.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Line; Disease Models, Animal; Gene Expression Profiling; Humans; Liver Neoplasms, Experimental; Mice; Mice, Nude; Naphthalimides; Organophosphonates; Stomach Neoplasms; Transplantation, Heterologous | 2011 |